Vera Therapeutics, INC 10-Q quarterly reports

Vera Therapeutics announced its second-quarter 2026 financial results, highlighting increased operating expenses and continued net losses, while also noting the accelerated approval of its lead product, TRUTAKNA.

Vera Therapeutics reported a net loss of $121.0 million for Q1 2026, with significant increases in R&D and G&A expenses, while advancing its lead product candidate, atacicept, for IgAN.

Vera Therapeutics reported significantly increased net losses and cash burn in Q3 2025, while advancing its lead product candidate, atacicept, with positive Phase 3 primary endpoint results and Breakthrough Therapy Designation.

Vera Therapeutics reports increased net losses in Q2 2025 as it advances its lead drug candidate, atacicept, through pivotal Phase 3 trials towards a planned Q4 2025 regulatory submission.

Vera Therapeutics reports a net loss of $51.7 million for Q1 2025, with significant R&D investment in its lead drug candidate, atacicept, and expects primary endpoint results in Q2 2025.

Vera Therapeutics' Q3 2024 filing reveals a significant increase in research and development expenses, primarily driven by manufacturing and clinical trial activities, alongside a substantial rise in cash and marketable securities.

Vera Therapeutics' Q2 2024 filing reveals increased research and development expenses, primarily driven by clinical trial and manufacturing activities, alongside a follow-on public offering that significantly boosted cash reserves.

Vera Therapeutics' Q1 2024 results show increased cash reserves due to a follow-on offering, while the company continues to invest in clinical development.